Download PDF
Zeitschrift für Palliativmedizin 2008; 9(4): 246-251
DOI: 10.1055/s-0028-1090086
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Thromboemboliebehandlung auch in der Palliativmedizin – ein Paradigmenwechsel?

Considerations for the Treatment of Venous Thromboembolism in Palliative CareB.  Alt-Epping1 , H.  Watzke2 , F.  Nauck1
  • 1Abteilung Palliativmedizin, Universitätsmedizin Göttingen
  • 2Klinik für Innere Medizin I, Palliativstation, Medizinische Universität Wien
Further Information

Publication History

Publication Date:
28 November 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Venöse Thromboembolien (VTE) führen nicht nur in operativen, allgemeininternistischen oder onkologischen Fachbereichen, sondern auch in der Palliativmedizin zu erheblicher Mortalität, Morbidität und Symptomlast. Die thromboemboliespezifischen Belastungen zu verhindern bzw. zu behandeln und dennoch die veränderten therapeutischen Prioritäten vor dem Hintergrund der letzten Lebensphase voranzustellen, stellt eine besondere Herausforderung in der Palliativmedizin dar. Diese Übersicht versucht, relevante Standards der allgemeinen Thromboemboliebehandlung und -prophylaxe und aktuelle hämostaseologische Aspekte onkologischer Grunderkrankungen so darzustellen, dass eine ausgewogene Bewertung in der palliativmedizinischen Therapieentscheidung erleichtert wird.

Abstract

Venous thromboembolism (VTE) leads to substantial mortality, morbidity and symptom burden not only in operative, medical or oncological, but also in palliative care settings. To prevent and treat these symptoms but to keep shifting priorities regarding aspects of end of life care in mind remains a major challenge in palliative care. This review article summarizes relevant standards for VTE treatment and prophylaxis, includes updated haemostaseologic insights in the care of cancer patients, and thereby tries to promote a balanced therapeutic assessment of palliative care decisions.

Schlüsselwörter

Thromboembolie - Primär- / Sekundärprophylaxe - Primärtherapie - Symptome

Key words

thromboembolism - primary / secondary prophylaxis - primary treatment - symptoms

Literatur

  • 1 Trousseau A. Phlegmasia alba dolens. In: Bailllier JB, ed Clinique de l'Hotel-Dieu de Paris, 2nd ed. London; New Sydenham Society 1865 3: 654-712
    Google Scholar
  • 2 Rosendaal F R. Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis.  Thromb Haemost. 1997;  78 1-6
    PubMedGoogle Scholar
  • 3 Moerchel C, Kroeger K. Prophylaxe tiefer Bein- und Beckenvenenthrombose.  Dt Ärzteblatt. 2007;  104 (42) A2886-2893
    PubMedGoogle Scholar
  • 4 Meignan M, Rosso J. et al . Systematic lung scans reveal a high frequenca of silent pulmonary embolism in patients with proximal deep venous thrombosis.  Arch Int Med. 2000;  160 159-164
    CrossrefPubMedGoogle Scholar
  • 5 Siddique R M, Siddiqu M I, Connors A F. et al . Thirty-day case-fatality rates for pulmonary embolism in the elderly.  Arch Int Med. 1996;  156 2343-2347
    CrossrefPubMedGoogle Scholar
  • 6 Douketis J D, Kearon C. et al . Risk of fatal thromboembolism in patients with treated venous thromboembolism.  JAMA. 1998;  279 458-462
    CrossrefPubMedGoogle Scholar
  • 7 Geerts W H, Pineo G F. et al., American College of Chest Physicians (ACCP) . Prevention of Venous Thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 (Suppl. 3) 338S-400S
    CrossrefPubMedGoogle Scholar
  • 8 Ulsenheimer K. Gutachterliche Aspekte der Thromboseprophylaxe.  Chirurg. 2007;  78 133-137
    CrossrefPubMedGoogle Scholar
  • 9 Mousa S A. Antithrombotics in thrombosis and cancer.  Hämostaseologie. 2005;  25 380-386
    PubMedGoogle Scholar
  • 10 Davila M, Amirkhosravi A, Coll E. et al . Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation.  J Thromb Haemost. 2008;  22 , epub ahead
    PubMedGoogle Scholar
  • 11 Kakkar A K, Lemoine N R, Scully M F. et al . Tissue factor expression correlates with histological grade in human pancreatic cancer.  Br J Surg. 1995;  82 1101-1104
    CrossrefPubMedGoogle Scholar
  • 12 Nitori N, Yoshinori I. et al . Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.  Clin Cancer Res. 2005;  11 2531-2539
    CrossrefPubMedGoogle Scholar
  • 13 National Comprehensive Cancer Network (NCCN) .Clinical Practice Guidelines in Oncology: Venous Thromboembolic Disease. 01 / 2006 http://www.nccn.org/professionals/physician_gls/PDF/VTE.pdf
    Google Scholar
  • 14 Mandalà M, Moro C, Labianca R. Venous thromboembolism and pancreatic cancer: incidence, pathogenesis and clinical implications.  Onkologie. 2008;  31 129-135
    CrossrefPubMedGoogle Scholar
  • 15 Sallah S, Wan J Y, Nguyen N P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics.  Thromb Haemost. 2002;  87 575-579
    PubMedGoogle Scholar
  • 16 Ogren M, Bergqvist D, Wahlander K. et al . Trousseau's syndrome – what is the evidence? A population-based autopsy study.  Thromb Haemost. 2002;  87 575-579
    PubMedGoogle Scholar
  • 17 Noble S. The challenges of managing cancer related venous thromboembolism in the palliative care setting.  Postgrad Med J. 2007;  83 671-674
    CrossrefPubMedGoogle Scholar
  • 18 Blom J W, Osanto S, Rosendaal F R. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients.  Eur J Cancer. 2006;  42 410-414
    CrossrefPubMedGoogle Scholar
  • 19 Martino M A, Williamson E, Siegfried S. et al . Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynaecologic oncology.  Gynaecol Oncol. 2005;  98 289-295
    CrossrefPubMedGoogle Scholar
  • 20 Sorensen H AT, Mellemkjaer L, Olsen J H. et al . Prognosis of cancers associated with venous thromboembolism.  N Eng J Med. 2000;  343 1846-1850
    CrossrefPubMedGoogle Scholar
  • 21 Khorana A A, Francis C W, Culakova E. et al . Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.  J Thromb Haemost. 2007;  5 632-634
    CrossrefPubMedGoogle Scholar
  • 22 Noble S, Hood K, Finlay I G. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of 62 patients.  Palliat Med. 2007;  21 473-476
    CrossrefPubMedGoogle Scholar
  • 23 Lee A YY, Levine M. et al . Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  NEJM. 2003;  349 (2) 146-153
    CrossrefPubMedGoogle Scholar
  • 24 Lee A Y, Rickles F R. et al . Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.  J Clin Oncol. 2005;  23 2123-2129
    Google Scholar
  • 25 Hutten B A, Prins M H, Gent M. et al . Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.  JCO. 2000;  18 3078-3083
    PubMedGoogle Scholar
  • 26 Prandoni P. Antithrombotic strategies in patients with cancer.  Thromb Haemost. 1997;  78 (Suppl.) 141-144
    PubMedGoogle Scholar
  • 27 Noble S, Shelly M, Coles B. et al . Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis.  The Lancet Oncology. 2008;  9 577-584
    CrossrefPubMedGoogle Scholar
  • 28 Lyman G H, Khorana A A. et al . American Society of Clinical Oncology guidelines: recommendations for venous thromboembolism prophylaxis and treatment in patients with advanced cancer.  J Clin Oncol. 2007;  25 5490-5505
    CrossrefPubMedGoogle Scholar
  • 29 Johnson M J, Sherry K. How do palliative physicians manage venous thromboembolism?.  Palliat Med. 1997;  11 (6) 462-468
    CrossrefPubMedGoogle Scholar
  • 30 Prandoni P, Lensing A W, Piccioli A. et al . Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.  Blood. 2002;  100 3484-3488
    CrossrefPubMedGoogle Scholar
  • 31 Barrit D W, Jordan S C. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial.  Lancet. 1960;  1 1309-1312
    PubMedGoogle Scholar
  • 32 Lagerstedt C I, Olsson C G. et al . Need for long-term anticoagulant treatment in symptomatic clf-vein thrombosis.  Lancet. 1985;  2 515-518
    PubMedGoogle Scholar
  • 33 Hull R, Delmore T, Genton E. et al . Warfarin sodium versus low-dose heparin in the long-term treatment of venous trombosis.  N Eng J Med. 1979;  301 855-858
    CrossrefPubMedGoogle Scholar
  • 34 Ambrus J L, Ambrus C W, Pickren C W. Causes of death in cancer.  J Med. 1975;  6 61-64
    PubMedGoogle Scholar
  • 35 Weber C, Merminod T, Herrmann F R. et al . Prophylactic anti-coagulation in cancer palliative care: a prospective randomized study.  Support Care Cancer. 2007;  16 (7) 847-852
    PubMedGoogle Scholar
  • 36 Monreal M, Zacharski L, Jiminez J A. et al . Fixed-dose low-molecular weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.  J Thromb Haemost. 2004;  2 1311-1315
    CrossrefPubMedGoogle Scholar
  • 37 Kierner K, Gartner V, Schwarz M. et al . Use of thromboprophylaxis in palliative care patients: a survey among experts in palliative care, oncology, intensive care and anticoagulation.  Am J Hosp Palliat Care. 2008;  25 (2) 127-131
    CrossrefPubMedGoogle Scholar
  • 38 Noble S, Finlay I G. Have palliative care teams' attitudes toward venous thromboembolism changed? A survey of thromboprophylaxis practice across British specialist palliative care units in the years 2000 and 2005.  J Pain Sympt Manage. 2006;  32 (19) 38-43
    CrossrefPubMedGoogle Scholar
  • 39 Noble S, Nelson A, Turner C. et al . Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study.  BMJ. 2006;  332 (7541) 577-580
    CrossrefPubMedGoogle Scholar
  • 40 Chambers J C. Prophylactic heparin in palliative care: to a challenging idea.  BMJ. 2006;  332 729
    PubMedGoogle Scholar
  • 41 Kirkova J, Fainsinger R L. Thrombosis and anticoagulation in palliative care: an evolving clinical challenge.  J Palliat Care. 2004;  20 (2) 101-104
    PubMedGoogle Scholar
  • 42 Kakkar A K, Levie M N, Kadziola Z. et al . Low molecular weight heparin, therapy with daltepatin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).  J Clin Oncol. 2004;  22 1944-1948
    CrossrefPubMedGoogle Scholar
  • 43 Christakis N, Lamont E. Extent and determinants of error in doctors' prognoses in terminally ill patients: a prospective cohort study.  BMJ. 2000;  320 469-473
    CrossrefPubMedGoogle Scholar

Dr. med. Bernd Alt-Epping

Abteilung Palliativmedizin, Zentrum Anaesthesiologie, Rettungs- und Intensivmedizin, Georg-August-Universität Göttingen

Robert Koch-Straße 40

37075 Göttingen

Phone: ++49-551-39 10501

Fax: ++49-551-39 10502

Email: bernd.alt-epping@med.uni-goettingen.de

      >